Daptomycin Market Global Industry Analysis By Share, Size, Opportunities, Challenges, Statistics, And Regional Forecast To 2027
Daptomycin Market
Overview
According to MRFR analysis, the Global Daptomycin Market is expected to register a CAGR of 4.4% during the forecast period 2020 to 2027 and reach USD 5,122.7 Million by 2027.
Daptomycin is a cyclic lipopeptide antibiotic derived from the organism Streptomyces rose sports. Daptomycin is used for the treatment of various bacterial infections caused by gram-positive bacteria.The growth of the global Daptomycin Market can be attributed to the high demand of daptomycin due to rising infections in the bloodstream, and increasing complicated skin and skin structure infections.
Furthermore, the
rise of right-sided infective endocarditis, and daptomycin as an antibacterial
drug, a bacterial metabolite and a member of calcium-dependent antibiotics, are
also expected to fuel the market growth during the forecast period.
However, increasing
rates of infection with gram-positive bacteria and the rapid emergence of
resistance to the new agent are expected to restrain the growth of the global
daptomycin market.
Several market
players such as Cipla, Pfizer, and Dr. Reddy’s Laboratories among others
currently dominate the global market.
Market Segmentation
Global Daptomycin Market has been segmented based
on Indication, Age Group, and Strength.
Based on indication, the global market has been
segmented into complicated skin structure infections, bacteremia, and others.
The complicated skin structure infections are expected to be the
fastest-growing segment during the forecast period.
Based on the age group, the market has been
segmented into pediatric and adult. The adult segment is expected to hold the
largest market share with an increasing number of bacteremia and right-sided
infective endocarditis patients.
Based on strength, the market is segmented into 350
mg and 500 mg.
Regional
Analysis
The market has been divided, by region, into the
Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas
region held the largest market in 2020, owing to the rising complicated skin
and skin structure infections in the region. The market in the Americas has further been branched
into North America and Latin America, with the North American market divided
into the US and Canada. The European market has been categorized as Western
Europe and Eastern Europe. The Western European market has further been
classified as Germany, France, the UK, Italy, Spain, and the rest of Western
Europe. The daptomycin market in Asia-Pacific has been segmented into China,
India, Japan, Australia, South Korea, and the rest of Asia-Pacific. Due to
rising infections in the bloodstream in the region, the market in Asia-Pacific
is expected to be the fastest-growing. The market in the Middle East &
Africa has been divided into the Middle East and Africa.
Key Players
Daptomycin Market
players are Teva Pharmaceutical Industries Ltd. (Israel),
Merck & Co (US), Cipla (India), Pfizer (US), BE Pharmaceuticals (US), Dr.
Reddy’s Laboratories (India), Mylan (US), Fresenius Kabi (Germany), Nichi-Iko
Pharmaceutical (Japan), Novo Holdings A/S (Denmark), Zhejiang Hisun (China),
Hengrui Medicine (China), Huadong Medicine (China), Civica Rx (US).
At Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private
Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment